What happened
On 5 October 2026, GE HealthCare signed a definitive agreement to buy SOFIE Biosciences, a U.S. contract manufacturer of PET radiopharmaceuticals, from private equity owner Trilantic North America for $945 million in cash. Closing is expected in the first half of 2027, subject to regulatory approvals, after which SOFIE will sit inside the Pharmaceutical Diagnostics (PDx) segment, the GE HealthCare unit that already supplies imaging agents used in around 140 million procedures in 2025.
What GE HealthCare is buying is physical reach rather than a single blockbuster product. SOFIE runs 15 contract manufacturing sites across the United States with 21 cyclotrons between them, plus one development and manufacturing site focused on theranostics. The deal also hands GE HealthCare the U.S. rights to FAPI-74, a Phase III fibroblast activation protein inhibitor PET tracer with pan-cancer imaging potential. GE HealthCare already controls the asset outside the U.S., so this closes a geographic gap in its own pipeline.
The buyer has committed to keep SOFIE open as an independent manufacturing partner after closing, still producing tracers for other radiopharmaceutical companies. GE HealthCare expects the business to grow in the low double digits under its ownership and says the transaction should add to revenue growth, adjusted EBIT margin and adjusted EPS in the first full year.
Why it matters
F18-labelled PET agents decay with a half-life of roughly 110 minutes. That single physical fact shapes the whole industry. A tracer made too far from the scanner loses much of its usable dose in transit, so production has to sit close to hospitals and imaging centers, and delivery runs on tight daily schedules. Whoever controls the cyclotron network in a region effectively controls which tracers patients can get, and how reliably.
For most of the past decade, large imaging and pharma companies developed the molecules while independent CMOs and radiopharmacies handled this last, time-critical leg. The SOFIE deal is a clear sign that the integrated model is winning. GE HealthCare already sells PET and SPECT scanners, digital workflow tools and a growing list of proprietary agents, including the cardiac tracer Flyrcado, which SOFIE already manufactures for it. Owning the regional production layer lets it line up scanner placements, tracer launches and supply commitments in one commercial conversation.
The timing also tracks the pipeline. GE HealthCare points to roughly 20 PET radiotracers and more than 30 radiotherapeutics in development industry-wide. Each new agent needs qualified manufacturing slots near patients, and cyclotron capacity takes years to permit, build and validate. Buying an operating network is faster than building one, and it secures launch capacity for FAPI-74 if the Phase III program reads out well.
For investors, the price looks like a strategic premium for scarce infrastructure rather than a bet on near-term earnings. At under $1 billion it is a modest check for a company of GE HealthCare’s size, but it shifts PDx from a product supplier that depends on partners into an owner of part of the U.S. supply chain.
Who feels it
Rival tracer developers. Companies that rely on SOFIE to make their own agents now have a key supplier owned by a direct competitor. GE HealthCare’s pledge to keep serving third parties will be tested on slot allocation, pricing and data confidentiality, especially when competing products need the same cyclotron time.
Independent radiopharmacies and CMOs. Remaining independent networks gain bargaining power as neutral partners, and some will likely become acquisition targets for other imaging or pharma groups that want the same control. Expect more interest in the regional assets that sit between drug developers and hospitals across healthcare and medical devices markets.
Hospitals and imaging centers. In the near term, little should change at the loading dock. Over time, providers may see bundled offers that pair scanners, software and tracer supply. That can improve reliability, but it can also reduce leverage on price and narrow choice between vendors.
Equipment and isotope suppliers. More capital behind cyclotron networks supports demand for targetry, hot cells, automated synthesis modules and quality-control systems. Suppliers of shielding, controlled transport and enriched target materials also benefit as networks expand and add newer isotopes.
What to watch
First, the regulatory path. Antitrust reviewers are likely to look closely at vertical overlap between GE HealthCare’s tracer portfolio and SOFIE’s role as a supplier to rivals, and remedies such as supply commitments to third parties are possible. Second, the FAPI-74 Phase III readout and filing timeline, since U.S. rights are a large part of the strategic value. A strong result would turn SOFIE’s network into a ready launch platform; a weak one leaves GE HealthCare with good infrastructure but less pipeline upside.
Third, watch whether competitors respond with their own manufacturing deals, which would confirm that control of final-mile supply has become the main battleground in nuclear medicine. Readers can track deal milestones and segment updates through GE HealthCare’s announcement of the SOFIE agreement, and should expect integration plans to sharpen once closing approaches in 2027.
For strategy teams, the takeaway is practical. In short half-life diagnostics, owning the molecule is no longer enough. Long-term advantage now goes to the companies that also own the clock, meaning the regional capacity that gets a dose from cyclotron to patient before it decays.